Exelixis puts fat wallet to work with Cybrexa, Sairopa deals - San Francisco Business Times

  • 📰 SFBusinessTimes
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 68%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

$EXEL's fat wallet beefs up its cancer drug pipeline

Exelixis Inc. President and CEOwarned that the company wasn't going to just sit on its cancer drug franchise, not with $2 billion in cash, equivalents and investments.

In the Sairopa deal, Exelixis will pay $40 million upfront and $70 million in near-term milestones for an exclusive, worldwide license to develop and sell Sairopa's ADU-1805. The drug is a monoclonal antibody targeting a protein — called signal regulatory protein alpha, or SIRPa — that protects cancer-associated proteins from being detected by the immune system's T cells and helps block the ability to clear tumor cells.

The moves were announced as Exelixis reported its third-quarter financials that showed the company with a $212.4 million profit through the first nine months of the year on revenue of nearly $1.19 billion.

 

コメントありがとうございます。コメントは審査後に公開されます。
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 78. in JP

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

An inside look into multi-family housing and the real estate market today - CEO SpotlightShakti C'Ganti, CEO, Ashland Greene Capital joins KRLD's David Johnson for this episode of CEO Spotlight.
ソース: KRLD - 🏆 75. / 68 続きを読む »

Orlando Tijuana Flats names restaurant veteran its new CEO - Jacksonville Business JournalHe replaces Brian Wright, who left after nearly four years with the company.
ソース: JaxBizJournal - 🏆 599. / 51 続きを読む »